Metagenomic Sequencing Market Size

Global Metagenomic Sequencing Market Overview

Metagenomic Sequencing Market Size valued at USD 0.5 Billion in 2022. The Metagenomic Sequencing market industry is projected to grow from USD 0.58 Billion in the year 2023 to USD 2.08 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 17.20% during the forecast period (2023 - 2032). Increased development of metagenomic sequencing and surging investment by the government and private sectors are the key market drivers enhancing growth of market.

Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review

Metagenomic Sequencing Market Trends

• Growing development in metagenomic sequencing is driving the market growth

Market CAGR for metagenomic sequencing is being driven by the rising development in metagenomic sequencing. The significant applications of metagenomics in different fields as it is essential in genomics, having applications in ecological and environmental metagenomics, bioremediation, and industrial use. The ability to study microbial communities from a wide variety of environments by scientists is expanding, thus increasing the demand for personalized medicine and growing funding for genomic research and technological advancement.

The advancement in data analysis tools and sequencing technologies has made metagenomic sequencing more affordable and accessible. The molecular biology study has been boosted by the development of the next DNA Sequencing technology, leading to a wealth of novel ideas and findings. Growing technological developments in DNA sequencing will probably fuel market expansion over a period of time. The government investment and financing for large-scale sequencing projects and also growing general knowledge of genetic abnormalities are the factors boosting the market growth. Several hereditary diseases with distinct clinical symptoms have been discovered. The rising adoption of next-generation sequencing technologies is also foreseen to fuel the growth of the market. The novel sequencing platform's development with enhanced accuracy, cost-effectiveness, and throughput has increased the adoption of NGS technologies for metagenomic sequencing.

The growing demand for metagenomic sequencing in environmental microbiome research and monitoring is anticipated to boost market growth. Pathogen detection through unbiased next-generation sequencing is possible with clinical diagnostic metagenomics. Bioinformatics technology and metagenomic sequencing have currently fueled the adoption of metagenomics-based accurate diagnostic procedures. Function-based screenings can help in discovering new proteins like antibodies by purifying, cloning, and expressing DNA extracted from the desired organism in a heterologous host, contributing to the growth of the market. Thus, driving the Metagenomic Sequencing market revenue.

However, the end-user budget constraints in some developing countries are one of the significant restraining factors in metagenomic sequencing experiments. Additionally, the social and economic impact of genomic medicine and research in emerging countries restrains market growth.

Metagenomic Sequencing Market Segment Insights

Metagenomic Sequencing Product & Service Insights

The Metagenomic Sequencing market segmentation, based on product & service, includes Reagents and Consumables, Instruments, and Services. The service segment dominates the market, accounting for the largest market revenue due to the higher utilization of metagenomic sequencing services and analysis and interpretation solutions of data. Further, the reagent and consumables segment is the second-largest contributor to the market segment, as the utilization of reagents and consumables has increased due to lower metagenomic sequencing error margins.

Figure 1 Metagenomic Sequencing Market, by Product & Services, 2022 & 2032 (USD Billion)

Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review

Metagenomic Sequencing Technology Insights

The Metagenomic Sequencing market segmentation, based on technology, includes shotgun metagenomic sequencing, 16s rRNA sequencing, whole genome sequencing and de novo assembly and metatranscriptomic. The 16s rRNA sequencing segment dominates the market as it is commonly utilized to classify, identify, and quantify microbes in complex biological mixtures like gut and environmental samples. Various manufacturers have designed newer techniques combined with 16s rRNA metagenomic sequencing that will assist in combating the conventional issues faced earlier. Further, the addition of an Internal Transcribed Spacer in combination with 16s rRNA is anticipated to offer a cost-effective technique for identifying strains that may not be found by using traditional methods.

Metagenomic Sequencing Regional Insights

By region, the study gives market insights into the North America, Europe, Asia-Pacific, and the Rest of the World. North American Metagenomic Sequencing market dominates the market due to the stronghold on deoxyribonucleic acid sequencing technologies because of the continuous improvement and availability and accessibility of DNA sequencing in the North American region. The US is the largest contributor to the growth of the metagenomic sequencing market in the North American region.

Further, the prime countries studied in the market report are the US, Canada, France, the UK, German, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil.

Figure 2 METAGENOMIC SEQUENCING MARKET SHARE BY REGION 2022 (USD Billion)

Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review

The Asia-Pacific Metagenomic Sequencing Market accounts for the second-largest market share due to the increasing emphasis of healthcare professionals on the drug discovery and development in the biotechnology industry. Moreover, China’s Metagenomic Sequencing market held the largest market share, and the Indian Metagenomic Sequencing market was the rapid-growing market in Asia-Pacific region.

Europe's Metagenomic Sequencing market is expected to grow at the rapid CAGR from 2023 to 2032. This is due to the growing investment by the government and hospitals for improved healthcare facilities in this region. Further, the German Metagenomic Sequencing market held the largest market share, and the UK Metagenomic Sequencing market was the rapid-growing market in the European region.

Metagenomic Sequencing Key Market Players & Competitive Insights

Leading market participants are investing hugely in research and development in order to expand their product lines, which will help the Metagenomic Sequencing market grow even more. Market players are also undertaking various strategic activities to spread their footprint, with important market developments inclusive of new product launches, mergers and acquisitions, higher investments, contractual agreements, and collaboration with other organizations. To spread and survive in a more competitive and rising market climate, the Metagenomic Sequencing industry must gives cost-effective items.

Manufacturing locally in orde to minimize operational costs is one of the key business tactics utilized by manufacturers in the Metagenomic Sequencing industry to benefit clients and increase the growth of market sector. In recent years, the Metagenomic Sequencing industry has offered some of almost all significant advantages to medicine. Major players in the Metagenomic Sequencing market, including Pattern AG, Illumina Inc., Thermo Fisher Scientific Inc., Swift Bioscience Inc., BGI Genomics Co. Ltd., Oxford Nanopore Technologies Ltd, Eurofins Genomics, Pacific Biosciences of California Inc., BGI Genomics Co Ltd., Macrogen Inc., AstraZeneca, and others, are trying to increase market demand by investing in the research and development operations.

Illumina Inc is an American biotechnology company founded in the year 1998, headquartered in San Diego, California, serving more than 140 countries. The company develops, produces, and sells integrated systems for the interpretation of genetic variation and biological function, providing a line of services and products that serves the genotyping, sequencing, gene expression, and proteomics markets. The company sells a variety of high-throughput DNA sequencing systems, depending on technology developed by Solexa. In April 2021, a partnership was announced by the company with Kartos Therapeutics, Inc. in order to co-develop a tumor protein (TP53) companion diagnostics (CDx) depending on the comprehensive genomic profiling content assay, TruSight Oncology of Illumina. This will expand the TruSight Oncology offerings into Illumine's hematologic malignancies. The company also announced an agreement with the Belgian Genetic Centers in order to evaluate whole-genome sequencing.

Pattern AG, founded in the year 2018, is a private company that has been in the industry for five years. The company specializes in the Biotechnology and Biotechnology areas; the company is headquartered in Emeryville, California, USA. Pattern AG detects the most damaging pathogens and pests in the fields. The company uses this data in order to predict the biggest threats to field problems. It analyzes soil biology to predict main-field agronomic outcomes with 90% confidence before the start of the season. This precise and advanced timing unlocks the profitability of the farm by enabling accurate product placement for key agronomic inputs. In April 2023, the company announced that it had generated the largest single ecosystem database based on genomics. This project emphasizes creating a  soil microbiome map that will assist in agro-genomics research.

Key Companies in the Metagenomic Sequencing market include

• Pattern AG


• Illumina Inc.


• Thermo Fisher Scientific Inc.


• 
  Swift Bioscience Inc.


• BGI Genomics Co. Ltd.


• Oxford Nanopore Technologies Ltd


• Eurofins Genomics


• Pacofic Biosciences of California Inc.


• BGI Genomics Co Ltd.


• Macrogen Inc.


• AstraZeneca

Metagenomic Sequencing Industry Developments

December 2020 ARTIC Next Generation Sequencing (NGS) service was launched by Eurofins. This ARTIC SARS-CoV-2 Whole Genome Sequencing service consists of NGS and detailed reporting for universal end-to-end surveillance of pandemic development.

February 2021 PacBio announced that Mercy Kansas City of Children increased its investment in highly accurate HiFi sequencing with four novels Sequel IIe Systems in order to add to its two existing Sequel IIe Systems.

September 2021 AstraZeneca and Thermo Fisher Scientific, Inc. co-developed an NGS-based companion diagnostic. The collaboration was emphasized on commercializing NGS-based diagnostics in Russia.

Metagenomic Sequencing Market Segmentation

Metagenomic Sequencing Product & Service Outlook

• Reagents and Consumables


• Instruments


• Services

Metagenomic Sequencing Technology Outlook

• Shotgun Metagenomic Sequencing


• 16s rRNA Sequencing


• Whole Genome Sequencing and De Novo Assembly


• Metatranscriptomic

Metagenomic Sequencing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America